Affimed signs $96M deal with Genentech to develop new cancer drug
Date: 2018-08-28   Author: Sunil Hebbalkar  Category: #news

Affimed signs $96M deal with Genentech to develop new cancer drug

Affimed N.V., has reportedly secured a $96 million investment and an opportunity to collaborate with the research team at Genentech. The collaboration is speculated to help Affimed develop an NK and T cell immunotherapies targeted towards multiple kinds of cancer.

Sources claim that the biotech firm may receive an additional $5.0 billion funding as milestone payments and royalties on sales. The collaboration with Genentech, which is a member of the Roche Group will focus on developing and commercializing Affimed’s new immunotherapeutics to treat cancer.

Based on the agreement, Affimed will discover an advanced and innate immune cell engager based immunotherapeutic focused on some goals Genentech has in mind. Affimed will direct its proprietary Redirected Optimized Cell Killing (ROCK), which helps produce T cell-engaging antibodies and NK cell, to help Affimed in developing the treatment for Genentech.

The collaboration will also include candidate products developed through Affimed’s ROCK platform and undisclosed hematologic tumor targets. The agreement will seemingly span multiple stages, right from discovery to late-stage research phases, reported sources.

Dr. Adi Hoess, Affimed’s CEO was quoted saying that Affimed is pleased to work with a company with proven expertise in oncology and excellence in generating cancer medication. He further addressed that the partnership is part of a strategy to explore the full potential of innate immune cells in oncology.

According to sources familiar with the matter, James Sabry, Global Head of Partnering at Roche Pharma, claimed that this partnership is a result of Affimed’s discovery of the innate immune cell drug and Genentech’s profound understanding of cancer immunology. The collaboration with Affimed provides an opportunity to improvise Roche’s efforts to understand the ways in which the immune system can be activated in order to combat cancer, he further commented.

Incidentally, Genentech will head the process of clinical development and commercialization of the product worldwide, claim reports.



About Author


Sunil Hebbalkar

Sunil Hebbalkar

Sunil currently works as an content writer at AlgosOnline. A Post graduate mechanical design engineer by qualification, he worked as an intern at the defense lab for one year in the engine design and development department before switching his professional genre. Foll...

Read More

More from Sunil


Post Recommendents

Mindtree partners with Bengaluru’s IISc to support AI research
Author: Paroma Bhattacharya

Bengaluru-based IT service provider, Mindtree Ltd. has recently collaborated with the Indian Institute of Science (IISc), Bangalore to create an endowment focused on AI research, and facilitate teaching and resear...


Asia Pacific Passive Fire Protection Materials Market will grow at 9.5% CAGR up to 2024
Author: Rahul Varpe

Based on the end-users, building & construction segment for passive fire protection materials market is projected to grow with CAGR of about 8.5% by 2024. This is attributed to strong persistence by regional regulatory bodies primarily in emer...


Tata Group in talks of acquiring a controlling stake in Jet Airways
Author: Ojaswita Kutepatil

Tata Group is reportedly inspecting Jet Airways’ books as the multinational corporation considers to grow its footprint in India’s growing air travel sector by potentially purchasing a stake in the cash-str...